Table 1 Association of HMMR expression and demographic and clinical characteristics in patients with gliomas
From: HELLPAR/RRM2 axis related to HMMR as novel prognostic biomarker in gliomas
Characteristic | TCGA | CGGA | ||||
|---|---|---|---|---|---|---|
Low | High | p | Low | High | p | |
n | 348 | 348 | Â | 346 | 347 | Â |
Gender, n (%) | Â | Â | 0.592 | Â | Â | 0.668 |
 Female | 153 (22%) | 145 (20.8%) |  | 144 (20.8%) | 151 (21.8%) |  |
 Male | 195 (28%) | 203 (29.2%) |  | 202 (29.1%) | 196 (28.3%) |  |
Age, meidan (IQR) | 40 (32, 51) | 53 (38, 63) |  < 0.001 | 42 (34, 50.75) | 43 (34.25, 53) | 0.246 |
Age, n (%) |  |  |  < 0.001 |  |  | 0.21 |
  <  = 60 | 312 (44.8%) | 241 (34.6%) |  | 316 (45.7%) | 305 (44.1%) |  |
  > 60 | 36 (5.2%) | 107 (15.4%) |  | 30 (4.3%) | 41 (5.9%) |  |
WHO grade, n (%) |  |  |  < 0.001 |  |  |  < 0.001 |
 G2 | 182 (28.7%) | 42 (6.6%) |  | 129 (18.6%) | 59 (8.5%) |  |
 G3 | 115 (18.1%) | 128 (20.2%) |  | 132 (19.1%) | 123 (17.8%) |  |
 G4 | 9 (1.4%) | 159 (25%) |  | 85 (12.3%) | 164 (23.7%) |  |
IDH status, n (%) |  |  |  < 0.001 |  |  | 0.006 |
 WT | 45 (6.6%) | 201 (29.3%) |  | 114 (17.8%) | 172 (26.8%) |  |
 Mut | 300 (43.7%) | 140 (20.4%) |  | 182 (28.3%) | 174 (27.1%) |  |
1p/19q codeletion, n (%) |  |  |  < 0.001 |  |  | 0.134 |
 codel | 121 (17.6%) | 50 (7.3%) |  | 74 (11.9%) | 71 (11.4%) |  |
 non-codel | 226 (32.8%) | 292 (42.4%) |  | 208 (33.4%) | 270 (43.3%) |  |
OS event, n (%) |  |  |  < 0.001 |  |  |  < 0.001 |
 Alive | 287 (41.2%) | 137 (19.7%) |  | 175 (26.4%) | 91 (13.7%) |  |
 Dead | 61 (8.8%) | 211 (30.3%) |  | 156 (23.5%) | 241 (36.3%) |  |
DSS event, n (%) |  |  |  < 0.001 |  |  |  |
 Alive | 288 (42.7%) | 143 (21.2%) |  |  |  |  |
 Dead | 53 (7.9%) | 191 (28.3%) |  |  |  |  |
PFI event, n (%) |  |  |  < 0.001 |  |  |  |
 Alive | 237 (34.1%) | 113 (16.2%) |  |  |  |  |
 Dead | 111 (15.9%) | 235 (33.8%) |  |  |  |  |